

4.06 TENOFOVIR ALAFENAMIDE/EMTRICITABINE, Tablet, tenofovir alafenamide 10 or 25mg and emtricitabine 200mg, Descovy[®], Gilead Sciences Pty Ltd.

1 Background

- 1.1 The sponsor made a submission to the July 2016 PBAC meeting to request a Section 100 Highly Specialised Drug Program (Community Access): Authority Required (Streamlined) listing for two strengths of the Descovy[®] fixed-dose combination (emtricitabine 200mg + tenofovir alafenamide 25mg or 10mg), for treatment of human immunodeficiency virus (HIV) for treatment-naïve patients and treatment-experienced patients.
- 1.2 The submission provided a cost-minimisation analysis of Descovy[®] versus the nominated comparator Truvada[®] based on drug cost only.
- 1.3 At the July 2016 meeting, the PBAC deferred making a recommendation on whether tenofovir alafenamide with emtricitabine should be listed on the Pharmaceutical Benefits Scheme for the treatment of HIV infection in order to hear the Department's views on matters relevant to the question of whether tenofovir disoproxil and tenofovir alafenamide should be declared as different drugs for the purposes of the Act.
- 1.4 At the July 2016 meeting, the PBAC formed the view that Descovy[®] (emtricitabine 200mg + tenofovir alafenamide 10 mg or 25mg tablet) is non inferior to Truvada[®] (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg tablet) in terms of effectiveness and safety. The equi-effective doses are:
 - Descovy[®] (emtricitabine 200mg / tenofovir alafenamide 10mg) in a pharmacokinetic boosted regimen;
 - Descovy[®] (emtricitabine 200mg / tenofovir alafenamide 25mg) in an un-boosted pharmacokinetic regimen; with
 - Truvada[®] (emtricitabine 200mg / tenofovir disoproxil fumarate 300mg), regardless of boosted or unboosted pharmacokinetic regimen.
- 1.5 The PBAC also considered the sponsor's request to have the restrictions for Truvada[®] to also apply to a listing of Descovy[®] to be appropriate. The PBAC formed the view that the Early Supply Rule should apply to Descovy, as recommended for all HIV treatments at the November 2015 meeting.
- 1.6 The PBAC decided it was not satisfied as required by subsection 101(4AC) and therefore would not provide advice to the Minister under that section.

2 Current situation



- 2.1 It has been longstanding practice for Pharmaceutical Benefits Advisory Committee (PBAC) recommendations under section 101(3) of the *National Health Act 1953* (the Act) and subsequent declarations under section 85(2) of the Act to be, in the most part, made at the level of the core active moiety, with salts, esters, and other groups determined as part of the form under section 85(3) of the Act.

- 2.2 The World Health Organisation’s International Non-proprietary Names (INN) list was identified as a source of guidance for identifying the core active moiety in a drug for sponsors, the PBAC, and the Minister. The INN may be useful in this regard as “An INN is usually designated for the active part of the molecule only, to avoid the multiplication of entries in cases where several salts, esters, etc. are actually used. In such cases, the user of the INN has to create a modified INN (INNM) himself; mepyramine maleate (a salt of mepyramine with maleic acid) is an example of an INNM.” (<http://www.who.int/medicines/services/inn/innquidance/en/>)
- 2.3 The PBAC or the Minister are not bound to follow INN conventions if a different approach is considered appropriate for particular drugs, taking into account chemical, structural, pharmacological, pharmacokinetic or other matters.

3 Sponsor’s response

- 3.1 The sponsor asserted that the HIV fixed dose combinations (FDCs) Descovy®, Odefsey® and Genvoya® all contain the drug ‘tenofovir alafenamide’ as the fumarate salt. This is distinct from the drug ‘tenofovir disoproxil’ as the fumarate salt, which is present in the FDC Truvada®, Eviplera® and Stribild®. Further, the sponsor stated that whilst both ‘tenofovir disoproxil’ and ‘tenofovir alafenamide’ are each prodrugs, neither is a prodrug of the other. They are distinct from each other chemically, structurally, pharmacologically and thus clinically different, as shown in figure 1 below.

Figure 1. Summary of characteristics of tenofovir disoproxil fumarate and tenofovir alafenamide

Tenofovir disoproxil fumarate (TDF)	Tenofovir alafenamide (TAF)
	
Poor plasma stability – converts to tenofovir (TFV) in plasma <ul style="list-style-type: none"> Undergoes rapid esterase hydrolysis to TFV in plasma TDF plasma half-life = 0.41 minutes (in vitro) TDF plasma half-life = not measurable (in vivo) TFV plasma half-life = 17 hours (in vivo) 	Greater plasma stability <ul style="list-style-type: none"> Remains intact in plasma TAF plasma half-life = 90 minutes (in vitro) TAF plasma half-life = 0.51 hours (in vivo) TFV plasma half-life = 32.37 hours (in vivo)
Converts to TFV in plasma. TFV has poor cell membrane permeability. Much of TFV is lost through renal excretion.	Greater cell membrane permeability
TFV enters target cell. <ul style="list-style-type: none"> Phosphorylated by nuclear kinase to TFV monophosphate (TFV-MP) TFV-MP rapidly converted by nucleotide diphosphate kinase to tenofovir diphosphate (TFV-DP) 	TAF enters target cell. <ul style="list-style-type: none"> Hydrolysis by lysosomal cathepsin A to intermediate metabolites which release TFV TFV phosphorylated to TFV-MP then TFV-DP
Lower intracellular TFV-DP achieved	4 times higher intracellular TFV-DP achieved
300 mg once daily dose	25 mg once daily dose

Source: Sponsor submission (p1)

- 3.2 The sponsor also claimed that the naming of tenofovir also has implications for Quality Use of Medicines (QUM) as TDF and TAF have different clinical indications with regard to age and renal impairment, and different dosing which could cause issues if confusion between the different drugs arises as a result of them both being named tenofovir.

4 PBAC outcome

- 4.1 The PBAC recommended the listing of emtricitabine + tenofovir alafenamide as a Section 100 (community access): Authority Required (STREAMLINED) listing for treatment-naïve and treatment-experienced patients with human immunodeficiency virus (HIV) on a cost-minimisation basis to Truvada®.
- 4.2 The PBAC noted the evidence presented by the sponsor that indicated tenofovir alafenamide and tenofovir disoproxil fumarate had differences in relation to dose, plasma stability, and metabolism. On this basis, the PBAC considered that tenofovir alafenamide should be considered different drug to tenofovir for the purposes of section 85(2) of the Act.
- 4.3 The PBAC recalled its previous advice (see paragraphs 1.3-1.6), particularly that Descovy® (emtricitabine 200mg + tenofovir alafenamide 10 mg or 25mg tablet) is non-inferior to Truvada® (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg tablet) in terms of effectiveness and safety and that the equi-effective doses are:
- Descovy® (emtricitabine 200mg / tenofovir alafenamide 10mg) in a pharmacokinetic boosted regimen;
 - Descovy® (emtricitabine 200mg / tenofovir alafenamide 25mg) in an un-boosted pharmacokinetic regimen; with
 - Truvada® (emtricitabine 200mg / tenofovir disoproxil fumarate 300mg), regardless of boosted or unboosted pharmacokinetic regimen.
- 4.4 The PBAC considered that the Early Supply Rule should apply to Descovy®, as recommended for all HIV treatments at the November 2015 meeting.
- 4.5 The PBAC noted that the brand Genvoya® was currently PBS-listed as a form (tenofovir alafenamide 10 mg + emtricitabine 200 mg + elvitegravir 150 mg + cobicistat 150 mg tablet) of the drug, tenofovir with emtricitabine, elvitegravir and cobicistat. The PBAC recommended that, consistent with its initial recommendation for Genvoya®, the drug in that medicine should be declared as tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat.
- 4.6 The PBAC noted that this submission was not eligible for Independent Review as it received a positive recommendation.

5 Recommended listing

- 5.1 Add new item:

Public Summary Document – November 2016 PBAC Meeting

Name, Restriction, Manner of administration and form	Max. Qty	No. of Rpts	Proprietary Name and Manufacturer	
EMTRICITABINE + TENOFOVIR ALAFENAMIDE emtricitabine 200mg + tenofovir alafenamide 25mg, tablet	60	5	Descovy® 25/200	Gilead Sciences Pty Ltd
emtricitabine 200mg + tenofovir alafenamide 10mg, tablet	60	5	Descovy® 10/200	Gilead Sciences Pty Ltd
Category / Program	Section 100 – Highly Specialised Drugs Program (Community Access)			
Condition	HIV infection			
Restriction	Authority Required (Streamlined)			
Treatment criteria	Treatment phase: Initial			
Clinical criteria	Patient must be antiretroviral treatment naïve AND The treatment must be in combination with other antiretroviral agents			
Category / Program	Section 100 – Highly Specialised Drugs Program (Community Access)			
Condition	HIV infection			
Restriction	Authority Required (Streamlined)			
Treatment criteria	Treatment phase: Continuing			
Clinical criteria	Patients must have previously received PBS-subsidised therapy for HIV infection AND The treatment must be in combination with other antiretroviral agents			

5.2 Amend item:

Name, Restriction, Manner of administration and form	Max. Qty	No. of Rpts	Proprietary Name and Manufacturer	
TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT tenofovir alafenamide 10 mg + emtricitabine 200 mg + elvitegravir 150 mg + cobicistat 150 mg tablet, 30	60	5	Genvoya®	Gilead Sciences Pty Ltd
Category/Program	Section 100 - Highly Specialised Drugs Program (Community Access)			
Condition	HIV infection			
Restriction	Authority Required (Streamlined)			
Treatment criteria	Treatment Phase: Initial			
Clinical criteria	Patient must be antiretroviral treatment naïve.			
Category/Program	Section 100 – Highly Specialised Drugs Program (Community Access)			
Condition	HIV infection			
Restriction	Authority Required (Streamlined)			
Treatment criteria	Treatment Phase: Continuing			
Clinical criteria	Patient must have previously received PBS-subsidised therapy for HIV infection.			

6 Context for Decision

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

7 Sponsor's Comment

The sponsor had no comment.